Selective Microbial Beta-Glucuronidase Inhibitors for Chemotherapy Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents like Irinotecan cause severe diarrhea due to microbial β-glucuronidase enzymes converting non-toxic metabolites into toxic forms in the intestines, leading to gastrointestinal distress and reduced treatment efficacy.
Innovation Solution
Development of selective microbial β-glucuronidase inhibitors, such as compounds of Formula I, which inhibit bacterial β-glucuronidases to prevent the reactivation of drug metabolites, thereby reducing side effects and improving the efficacy of chemotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents like Irinotecan are administered to treat cancer, then cancer treatment efficacy is improved, but severe diarrhea and gastrointestinal distress occur due to microbial β-glucuronidase enzyme activity
Solution Approach 1:
The patent introduces selective microbial β-glucuronidase inhibitors as intermediary substances that mediate between the chemotherapeutic agent and the harmful enzyme. These inhibitors bind to the microbial β-glucuronidase enzyme, preventing it from converting the non-toxic Irinotecan metabolite into the toxic active form, thereby protecting the gastrointestinal tract while allowing cancer treatment to proceed
Solution Approach 2:
The patent extracts and targets the harmful microbial β-glucuronidase enzyme activity from the gastrointestinal environment. By developing selective inhibitors that specifically target this enzyme without affecting human cells or other gut microbiota, the patent removes the harmful conversion function while preserving the beneficial cancer treatment effect
2Object-affected harmful factors
If microbial β-glucuronidase inhibitors are developed to prevent reactivation of drug metabolites, then gastrointestinal toxicity is reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent segments the treatment approach into two independent components: the chemotherapeutic agent for cancer treatment and the selective β-glucuronidase inhibitor for toxicity prevention. This segmentation allows each component to be optimized independently and administered separately, reducing the complexity compared to a single multi-functional drug
Solution Approach 2:
The patent utilizes parameter changes in the chemical structure of the inhibitors to achieve selective binding to microbial β-glucuronidase. By modifying molecular parameters such as binding affinity and selectivity, the patent creates inhibitors that are highly specific to the target enzyme, thereby reducing off-target effects and simplifying the treatment profile
3Reliability
If selective microbial β-glucuronidase inhibitors are used, then treatment specificity is improved, but the risk of harmful effects on non-target organisms increases
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that confer selective binding to microbial β-glucuronidase. The inhibitor structure includes specific interactions (such as hydrogen bonding and hydrophobic interactions) that are unique to the microbial enzyme's active site, thereby achieving high specificity and minimizing off-target effects on human cells or other microbiota
Solution Approach 2:
The patent converts the potential harm of broad-spectrum enzyme inhibition into a benefit by designing selective inhibitors that target only the harmful microbial β-glucuronidase activity. This selective approach transforms a potentially harmful non-specific inhibition into a beneficial specific action that protects against toxicity while preserving normal physiological functions
Data Source
AI summary
Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.